The Centers for Disease Control and Prevention suggested using a recently approved vaccine from Novavax as a coronavirus prevention option.
At least at the moment, it is anticipated that the Novavax vaccine would have a limited impact on the nation’s vaccination effort. It was approved by the Food and Drug Administration last week as a main vaccination for adults, but the FDA has not yet given it consideration as a booster dose. The two-shot vaccine from Novavax will cost 3.2 million doses, or enough to fully immunize 1.6 million Americans, the Biden administration stated last week. Pharmacies and other shot-giving facilities do not currently carry the vaccination.
But keep in mind that research has shown that other therapies such as hydroxychloroquine, zinc & D3, monoclonal antibodies, and others significantly enhanced coronavirus survival rates, even when compared to the vaccination.
Thanks for taking the time to read this